| Literature DB >> 22455503 |
Juliane Wolf1, Birgit Weinberger, Beatrix Grubeck-Loebenstein.
Abstract
BACKGROUND: As a chronic antigenic stressor human Cytomegalovirus (CMV) contributes substantially to age-related alterations of the immune system. Even though monocytes have the greatest propensity for CMV-infection and seem to be an important host for the virus during latency, fibroblasts are also discussed to be target cells of CMV in vivo. However, little is known so far about general immunoregulatory properties of CMV in fibroblasts. We therefore investigated the immunoregulatory effects of CMV-infection in human lung fibroblasts and the impact on replicative senescence.Entities:
Year: 2012 PMID: 22455503 PMCID: PMC3364840 DOI: 10.1186/1742-4933-9-1
Source DB: PubMed Journal: Immun Ageing ISSN: 1742-4933 Impact factor: 6.400
Differently expressed genes in early versus replicative senescent and CMV-infected versus untreated human lung fibroblasts
| Gene symbol | Gene name | Fold regulation in | Maximally observed fold regulation (mean ± S.E.M.) following CMV-infection | |
|---|---|---|---|---|
| CASP1 | Caspase 1 | - | 2.4 ± 1.3 | |
| CASP4 | Caspase 4 | - | 2.3 ± 1.3 | |
| TGFB1 | Transforming growth factor, beta 1 | - | 2.1 ± 0.9 | |
| TNFRSF1A | Tumor necrosis factor receptor superfamily, member 1A | - | 2.4 ± 1.6 | |
| C5 | Complement component 5 | - | 2.3 ± 1.5 | |
| C8A | Complement component 8, alpha polypeptide | 6.8 ± 0.8 | - | |
| CD55 | CD55 molecule, accelerating factor for complement | - | 4.3 ± 0.9 | |
| CCL2 | Chemokine (C-C motif) ligand 2 | - | 2.8 ± 1.8 | |
| CXCR4 | Chemokine receptor 4 | - | 57.8 ± 1.5 | |
| IFNA1 | Interferon, alpha 1 | 3.7 ± 0.3 | - | |
| 2.0 ± 0.4 | 3.2 ± 1.6 | |||
| IFNGR2 | Interferon gamma receptor 2 | - | 2.2 ± 1.6 | |
| 6.4 ± 0.2 | 6.4 ± 1.6 | |||
| 4.1 ± 0.1 | 8.9 ± 1.7 | |||
| IL1F5 | Interleukin 1 family, member 5 | 3.2 ± 1.2 | - | |
| IL1F7 | Interleukin 1 family, member 7 | 8.9 ± 0.8 | - | |
| 10.2 ± 0.04 | 8.1 ± 1.5 | |||
| TNF | Tumor necrosis factor | 3.2 ± 0.4 | - | |
| TLR2 | Toll-like receptor 2 | - | 6.1 ± 5.4 | |
| TLR3 | Toll-like receptor 3 | - | 5.9 ± 3.9 | |
| 3.8 ± 0.9 | 5.4 ± 4.7 | |||
| TLR6 | Toll-like receptor 6 | 3.0 ± 0.2 | - | |
| TOLLIP | Toll interacting protein | - | 2.5 ± 1.3 | |
| CAMP | Cathelicidin antimicrobial peptide | 8.3 ± 0.6 | - | |
| FN1 | Fibronectin 1 | 2.5 ± 0.2 | - | |
| IL1R1 | Interleukin 1 receptor, type I | - | 2.9 ± 1.2 | |
| IL1RL2 | Interleukin 1 receptor-like 2 | - | 5.3 ± 2.5 | |
| IL1RAP | Interleukin 1 receptor accessory protein | - | 2.4 ± 1.8 | |
| IKBKB | Inhibitor of kappa light polypeptide gene enhancer | 2.8 ± 0.2 | - | |
| MAPK8 | Mitogen activated protein kinase 8 | - | 2.5 ± 1.5 | |
| MAPK14 | Mitogen activated protein kinase 14 | - | 2.5 ± 1.3 | |
| 12.2 ± 3.0 | 4.2 ± 4.2 | |||
| CCR3 | Chemokine (C-C motif) receptor 3 | 12.3 ± 0.8 | - | |
| CD14 | CD14 molecule | 29.1 ± 1.0 | - | |
| CYBB | Cytochrome b-245, beta polypeptide | 8.5 ± 0.5 | - | |
| IRAK1 | Interleukin-1 receptor-associated kinase 1 | - | 3.2 ± 1.7 | |
| 2.4 ± 0.04 | 2.7 ± 1.5 | |||
| NOS2A | Nitric oxide synthase 2A (inducible) | 4.7 ± 0.9 | - | |
| PTAFR | Platelet-activating factor receptor | 4.5 ± 1.4 | - | |
| DMBT1 | Deleted in malignant brain tumors 1 | 8.9 ± 1.4 | - | |
| PGLYRP1 | Peptidoglycan recognition protein 1 | 10.7 ± 1.8 | - | |
| PGLYRP3 | Peptidoglycan recognition protein 3 | 12.0 ± 1.1 | - | |
| SFTPD | Surfactant, pulmonary-associated protein D | 10.0 ± 1.1 | - | |
| CHUK | Conserved helix-loop-helix ubiquitous kinase | - | 2.1 ± 1.3 | |
| MyD88 | Myeloid differentiation primary response gene | - | 3.9 ± 1.8 | |
| NFKB2 | Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 (p49/p100) | - | 3.2 ± 1.6 | |
| NFKBIA | Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha | - | 2.0 ± 0.9 | |
| TRAF6 | TNF receptor-associated factor 6 | - | 2.3 ± 1.5 | |
| COLEC12 | Collectin subfamily member 12 | 2.2 ± 0.2 | - | |
| HMOX1 | Heme oxygenase 1 | - | 2.0 ± 1.0 | |
| IRF1 | Interferon regulatory factor 1 | - | 3.4 ± 1.8 | |
| LY96 | Lymphocyte antigen 96 | - | 2.6 ± 1.7 | |
| 2.3 ± 0.2 | 2.7 ± 1.6 | |||
| 4.1 ± 1.1 | 10.0 ± 2.8 | |||
The fold regulation data represent the mean ± S.E.M. of three independent experiments calculated for each examined group and time point.
Figure 1BioVenn diagram showing the number of immunity-related genes upregulated in replicative senescent and CMV-infected fibroblasts. Shown is the number of genes differentially expressed in late passage compared to early passage fibroblasts (senescence) and the number of genes differentially expressed in CMV-infected versus untreated fibroblasts (CMV). 9 genes are regulated in both analyses. Depicted are genes that were reproducibly regulated in three independent experiments.
Figure 2mRNA levels of IFNGR1, ADORA2A and IL6 over time in CMV-infected fibroblasts. Human lung fibroblasts were in vitro infected with CMV. Cells were harvested at the indicated time points, total RNA was isolated and gene expression of (A) IFNγ receptor 1 (IFNGR1), (B) adenosine A2A receptor (ADORA2A) and (C) Interleukin-6 (IL6) was analyzed using a RT2 Profiler PCR Array. Gene expression of CMV-infected fibroblasts was calculated in relation to gene expression of mock-infected fibroblasts. IFNGR1 and ADORA2A were maximally upregulated 24 hours post infection. While IFNGR1 expression returned to basal levels after 48 hours, ADORA2A was relatively stable expressed over time. In contrast IL6 showed a continuous upregulation of gene expression with a maximum at 72 hours following CMV-infection. The arithmetic mean ± S.E.M. were calculated for each examined group and time point (three independent experiments).
Figure 3IL6 protein levels in the supernatant of human fibroblasts following . Human lung fibroblasts were left untreated (mock) or infected with the CMV strain Town-eGFP. IL6 protein secretion of mock- and CMV-infected fibroblasts was analyzed by ELISA over a time period of 5 days. The arithmetic mean ± S.E.M. were calculated for each examined group and time point. Comparisons between two groups were analyzed by Student's t-test, using SPSS version 19.0 (SPSS Inc., Chicago, Illinois, USA). p values below 0.05 were considered as statistically significant. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.